Abstract
Introduction
The use of serum biomarkers has been successfully demonstrated in the clinical context of cardiovascular diseases (CVDs) and bone metabolism disorders, and their predictive value as well as discriminatory power has been well established [1] . Both [2, 3] . [4, 5] . Data integration, bioinformatics analyses and functional testing of novel hypotheses drawn have been identified as a valuable strategy, commonly denoted in the context of systems biology [6] .
-CVDs and bone metabolism disorders -might be causally linked in patients with chronic kidney disease (CKD), because the disturbances of the calcium-, phosphate-, vitamin D-and parathyroid hormone (PTH) metabolism, as well as the incidence of cardiovascular events as myocardial infarction rises early in the course of kidney disease
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Mondry and colleagues emphasized the potential of systems biology and quantitative models in their review on the molecular mechanisms of renal osteodystrophy [7] . Drake et al. focused on proteomic approaches and the use of protein-protein interaction data for biomarker discovery in their review on systems biology of CVDs [8] .
This
review provides an overview on the suspected link between CVDs and bone metabolism disorders in patients with impaired renal function, and will furthermore characterize and analyse reported biomarkers associated with these particular diseases. Subsequently, the interdependency of reported biomarkers will be analysed on a systems biology level taking into account data on gene expression in CKD, functional gene annotation, protein-protein interactions, as well as gene regulatory elements reflected by joint transcription factor binding sites.
Kidney disease and cardiovascular risk
CKD is associated with increased risk for cardiovascular complications and all cause mortality. The risk of death and the prevalence of CVD start to rise significantly already in patients with early stage renal insufficiency, i.e. with a glomerular filtration rate (GFR) of less than 60 ml/min. [9] . In dialysis patients the prevalence of CVD and the mortality due to CVD is even 10 to 30 times higher than in the general population [10] [17, 20] . [32, 33] , and are listed in Tables 3 and 4 
advanced glycation products, cytokines as interleukines (mostly IL-1, IL-6 and IL-11), soluble IL-6 receptor, tumour necrosis factor-␣ (TNF-␣), transforming growth factor-␤ (TGF-␤), bone morphogenetic proteins (BMPs) and their soluble receptors, growth factors such as insulin growth factor-1 (IGF-1), macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor
Functional annotation
Functional categories as well as molecular pathways holding a significant number of genes were identified using the Gene Expression Data Analysis Tool of the PANTHER (protein analysis through evolutionary relationships) Classification System
Protein-protein interaction network analysis
Next to identifying joint functional categories we used human protein-protein interaction data to determine the connectivity of the 77 [20] biomarker candidates on the level of cellular protein networks. Fig. 1a . Fig. 1 4982 [17] sub-graph as given in Fig. 1 [43, 44] . Besides its function in haemostasis PLAU is also involved in cell attachment and deformation of the extracellular matrix [45] . [46] . SER-PINE1 plasma concentrations are elevated in patients with increased risk of ischaemic cardiovascular events [47] . All three chains of fibrinogen are part of the network. After cleavage by thrombin, fibrin fibres form blood clots after vascular injury.
Human protein-protein interaction data from OPHID (Online Predicted Human Interaction Database) were used for the analysis (OPHID Version 2007-02-17) [34]. The generation of interaction networks followed the next neighbour expansion method as proposed by Chen et al. [35]. OPHID represents protein interactions as protein A interacts with protein B. If A and B are members of the list of 77 candidates a positive interaction is identified. The next neighbour expansion also includes interactions of the type A-X-B, where X represents a protein not given in the initial candidate list. All interacting partners of the initial set of 77 proteins were extracted from the OPHID database and the protein interaction network was generated. At least one interacting partner was found for 29 of the 31 CVD, and for 38 of the 46 bone metabolism markers. The resulting graph, composed of one large sub-graph and a number of smaller, disconnected sub-graphs, consisted of 353 protein nodes and 440 protein interaction edges, as depicted in
The index of aggregation (IA) serves as aggregation and complexity measure of interaction networks for evaluating if the interaction characteristics differ with respect to networks derived on the basis of random protein lists. This measure therefore gives an indication if the connectivity for a given protein list is higher than statistically expected. The IA is given as percentage of protein nodes in the largest sub-graph with respect to all protein nodes in the network including all sub-graphs. The IA of the biomarker candidates' network given in
Integrated analysis
For further characterizing the interrelation between all 353 members of the interaction network represented by the largest
Members of the second sub-network are collagen, type I, ␣1 (COL1A1), the TGF-␤1, the plasminogen activator inhibitor, also known as serpin peptidase inhibitor, clade E (SERPINE1), and the ␣, ␤ and ␥ chains of fibrinogen (FG-␣, FG-␤, FG-␥). COL1A1 is like COL1A2 found in most connective tissues. TGF-␤1 is a multifunctional protein involved in proliferation, differentiation, apoptotic processes, cell adhesion, and tissue remodelling
Conclusion and outlook
We provide an interactome analysis approach to characterize the interplay of reported biomarker candidates for CVDs and bone [48, 49] . This development allows the analysis of the functional interplay among biomarker candidates, clearly providing routes towards identifying improved candidate markers.
